eligibility_summary
Adults (≥18) with r/r CD70+ glioma (IHC ≥2+, recent or ≤2‑yr tissue), measurable/evaluable (RANO), KPS ≥70, life expectancy ≥12 wks, adequate marrow/liver/renal/coagulation, prior tox ≤G1, contraception required. Exclude prior CD70 tx, recent investigational/systemic tx, RT, other cell tx, steroids/anticoagulants, other malignancy (except cured), transplants, immunodeficiency/autoimmune, live vaccines, severe/unstable or major CV disease, active HIV/syphilis/HBV/HCV/CMV/EBV, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Allogeneic CD70-directed CAR-T cells (biologic, donor-derived engineered T lymphocytes) given intrathecally (1×10^6/kg) to adults with relapsed/refractory CD70-positive gliomas. Mechanism of action: CAR with an anti-CD70 binding domain redirects donor T cells to recognize CD70 on tumor cells independent of MHC, activating T-cell signaling (e.g., CD3ζ with costimulation) to induce perforin/granzyme-mediated cytotoxicity and cytokine-driven antitumor effects. Targets: CD70-expressing glioma cells in the CNS, pathways include the CD70 antigen on tumor cells and downstream T-cell effector activation cascades leading to malignant cell elimination. Primary focus: safety, preliminary efficacy, and immune profiling.